However, the majority of ER+ breast cancer is HER2− at diagnosis, and while ~70% of ER+/HER2− breast cancer patients respond well to endocrine therapy, ~30% of patients become resistant to endocrine treatment resulting in relapse, metastasis, and death2,6. This evidence concerns the gene ESR1 and breast carcinoma.